Prospective clinical trial of gelatin‐thrombin matrix as first line treatment of posterior epistaxis
- 28 June 2013
- journal article
- clinical trial
- Published by Wiley in The Laryngoscope
- Vol. 124 (1) , 38-42
Abstract
Objectives/Hypothesis To evaluate the effectiveness of gelatin‐thrombin matrix for first line treatment of posterior epistaxis. Secondarily, we evaluated discomfort during treatment and the cost savings of treatment with gelatin‐thrombin matrix compared to posterior packing, endoscopic, or endovascular treatment at our institution. Study Design Prospective pilot, nonblinded, noncontrolled registered clinical trial (NCT01098578). Methods Twenty patients with posterior epistaxis were enrolled into this study. Gelatin‐thrombin matrix was used for posterior epistaxis treatment with simultaneous ipsilateral choanal occlusion. Patients were discharged within 2 hours of being successfully treated. A visual analog scale (range 0–10) was used to assess treatment discomfort. Patients were evaluated in clinic 5 and 30 days after treatment to assess for intranasal complications and recurrent epistaxis. Results Gelatin‐thrombin matrix successfully treated epistaxis in 80% of the patients. The procedure was associated with a mean discomfort of 3.6 (range 0–9.7). The institutional per case cost of treatment of patients with posterior epistaxis with gelatin‐thrombin matrix is 80.3%, 87.4%, and 89.4% less than with endoscopic surgery, posterior packing, or embolization, respectively. There were no complications. Conclusion This pilot study demonstrated that gelatin‐thrombin matrix is a safe and both a clinically effective and cost‐saving means of treating posterior epistaxis. In this study, its use is associated with a low level of discomfort. This treatment method may improve the quality of care for patients with posterior epistaxis. Level of Evidence 4. Laryngoscope, 124:38–42, 2014Keywords
This publication has 27 references indexed in Scilit:
- Sphenopalatine, anterior ethmoid and internal maxillary artery intervention in the management of refractory epistaxis: Their efficacy in 25 patientsClinical Otolaryngology, 2012
- Endoscopic Ligation of the Sphenopalatine Artery and the Maxillary Artery for the Treatment of Intractable Posterior EpistaxisAmerican Journal of Rhinology & Allergy, 2009
- The Rhinology Experience in Otolaryngology Residency: A Survey of Chief ResidentsThe Laryngoscope, 2008
- Outcome of Endoscopic Sphenopalatine Artery Occlusion for Intractable Epistaxis: A 10‐Year ExperienceThe Laryngoscope, 2007
- Controlled Survival Study of the Effects of Tisseel or a Combination of FloSeal and Tisseel on Major Vascular Injury and Major Collecting-System Injury during Partial Nephrectomy in a Porcine ModelJournal of Endourology, 2005
- Prospective, Randomized, Controlled Clinical Trial of a Novel Matrix Hemostatic Sealant in Patients with Acute Anterior EpistaxisThe Laryngoscope, 2005
- Use of Gelatin Matrix Thrombin Tissue Sealant as an Effective Hemostatic Agent During Laparoscopic Partial NephrectomyJournal of Urology, 2004
- Contemporary surgical treatment of epistaxis. What is the evidence for sphenopalatine artery ligation?Clinical Otolaryngology, 2003
- Use of FloSeal Hemostatic Sealant in Transsphenoidal Pituitary Surgery: Technical NoteNeurosurgery, 2002
- Epistaxis: Medical versus surgical therapy: A comparison of efficacy, complications, and economic considerationsThe Laryngoscope, 1987